Advansource Biomaterials Corp (ASNB) financial statements (2020 and earlier)

Company profile

Business Address 229 ANDOVER STREET
WILMINGTON, MA 01887
State of Incorp. DE
Fiscal Year End March 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0000000
Cash and cash equivalents0000000
Receivables00     
Inventory, net of allowances, customer advances and progress billings0000000
Inventory0000000
Prepaid expense00     
Deferred costs     00
Other undisclosed current assets0010000
Total current assets:0010111
Noncurrent Assets
Property, plant and equipment0022222
Deposits noncurrent assets00     
Other undisclosed noncurrent assets0000000
Total noncurrent assets:0022222
TOTAL ASSETS:0032333
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities00     
Accounts payable00     
Accrued liabilities00     
Customer advances and deposits0000
Other undisclosed current liabilities0011011
Total current liabilities:0011111
Noncurrent Liabilities
Liabilities, other than long-term debt    00 
Accounts payable and accrued liabilities    00 
Other undisclosed noncurrent liabilities0022222
Total noncurrent liabilities:0022222
Total liabilities:0033333
Stockholders' equity
Stockholders' equity attributable to parent, including:(0)(0)(1)(1)(0)(0)0
Common stock0000000
Treasury stock, value  00000
Additional paid in capital003838383838
Accumulated deficit(0)(0)(39)(39)(38)(38)(38)
Other undisclosed stockholders' equity attributable to parent  (0)(0)(0)(0)(0)
Other undisclosed stockholders' equity(0)(0)     
Total stockholders' equity:(0)(0)(1)(1)(0)(0)0
TOTAL LIABILITIES AND EQUITY:0032333

Income statement (P&L) ($ in millions)

9/30/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
Revenues(1)032 33
Revenue, net32 33
Cost of revenue
(Cost of Goods and Services Sold)
0(0)(1)(1)(85)(1)(1)
Gross profit:(0)021(85)22
Operating expenses0(0)(2)(2)(310)(2)(2)
Other operating expense, net
(Other Expenses)
     (0)(0)
Operating income (loss):000(0)(395)(0)(1)
Nonoperating income
(Investment Income, Nonoperating)
00     
Interest and debt expense0 (0)(0) (0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes0      
Income (loss) from continuing operations before equity method investments, income taxes:10(0)(1)(395)(1)(1)
Other undisclosed loss from continuing operations before income taxes(1)(0)     
Income (loss) before gain (loss) on sale of properties:00(0)(1)(395)(1)(1)
Other undisclosed net income0      
Net income (loss):00(0)(1)(395)(1)(1)
Other undisclosed net income attributable to parent    39500
Net income (loss) available to common stockholders, diluted:00(0)(1)0(0)(1)

Comprehensive Income ($ in millions)

9/30/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
Net income (loss):00(0)(1)(395)(1)(1)
Comprehensive income (loss), net of tax, attributable to parent:00(0)(1)(395)(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: